{"article":{"annotation":{"article_id":"uk-mhra-casgevy-gene-editing-children-approval-2026","available_at":"2026-10-31T22:01:35.243807Z","geography_revision":"ef6ee0010dda5fe7b240fd514749b43e214c57da73222d2e40ec83b276dd0977","id":"73e5787d01f79339b1ec7ad665d4938e2c3538a559a574d0072d8ad4295b74e2","input_sha256":"8c3799cf62f8e1726fae6b905be37be706533b0df1ef6368542181fcb4b77d71","limitations":["Rule-derived subjects are candidates, not verified editorial labels or calibrated model probabilities.","Coverage is distinct from event location. Unknown country/city/coordinates remain absent; no automatic geocoding.","Article geometries keep their stated precision and methodology; reproducing them is not independent coordinate verification."],"method":"controlled-rules-v1","places":[{"admin1":null,"city":null,"coordinate_note":null,"coordinate_reference_system":"OGC:CRS84","coordinate_source":null,"country":"GB","evidence":[{"field":"country","language":"en","note":"Explicit preserved editorial country/region; no city or national centroid inferred","source_urls":["https://www.gov.uk/government/news/mhra-approves-gene-editing-treatment-for-children-aged-five-and-over-with-serious-inherited-blood-disorders"]}],"geometry":null,"id":"iso3166-1:GB","kind":"country-or-area","labels":{"ar":"المملكة المتحدة لبريطانيا العظمى وآيرلندا الشمالية","en":"United Kingdom of Great Britain and Northern Ireland","es":"Reino Unido de Gran Bretaña e Irlanda del Norte","fr":"Royaume-Uni de Grande-Bretagne et d’Irlande du Nord"},"match_status":"candidate","precision":"regional","role":"coverage","uncertainty_m":null}],"rules_sha256":"fb5ad3c27c91cb840f7a0a05f7f64a5cb26ad0374409ff9457f277c7092e22b4","schema_version":1,"subjects":[{"concept_id":"medtop:07000000","confidence":null,"confidence_method":null,"evidence":[{"field":"en.title+en.summary","language":"en","note":"Subject suggested from the title or summary: Healthcare, disease","source_urls":["https://www.gov.uk/government/news/mhra-approves-gene-editing-treatment-for-children-aged-five-and-over-with-serious-inherited-blood-disorders"]}],"method":"controlled-rules-v1","rule_id":"health","status":"candidate"}],"taxonomy_revision":"1f2db31d811fca07e99b16d402c10e2cc2965c9df1c7b41d9be348b40a24e7fb","taxonomy_version":"IPTC Media Topics 2026-Q2"},"api_url":"https://newsverum.com/api/v1/articles/uk-mhra-casgevy-gene-editing-children-approval-2026?lang=en","category":"health","content":{"key_points":[],"paragraphs":["The UK Medicines and Healthcare products Regulatory Agency announced on 29 October that it has expanded the authorisation for the CRISPR-based gene therapy Casgevy to children aged five and older with severe sickle-cell disease and transfusion-dependent beta-thalassaemia.","Casgevy (exagamglogene autotemcel) was previously restricted to patients aged 12 and above. The therapy edits the patient’s harvested haematopoietic stem cells in a laboratory to reactivate fetal haemoglobin production, before reinfusing them following myeloablative conditioning.","The regulator confirmed that the expansion follows evaluation of clinical trials demonstrating significant reductions in vaso-occlusive pain crises and transfusion dependency in younger age cohorts. Treatment requires specialized cell-therapy centres and rigorous post-infusion monitoring for complications such as cytopenias and infections."],"sections":[]},"corrections":[],"country":"GB","data":{"blocks":[{"description":{"ar":"نشر إعلان توسيع الموافقة الرسمي في 29 أكتوبر 2026.","de":"Veröffentlichung der offiziellen Mitteilung zur Zulassungserweiterung am 29. Oktober 2026.","en":"Publication of the official approval extension announcement on 29 October 2026.","es":"Publicación del comunicado oficial de ampliación de autorización el 29 de octubre de 2026.","fr":"Publication du communiqué officiel d'élargissement de l'autorisation le 29 octobre 2026.","pt":"Publicação do anúncio oficial de alargamento da autorização em 29 de outubro de 2026.","tr":"29 Ekim 2026’da resmî onay genişletme duyurusunun yayımlanması."},"id":"source-announcement","items":[{"date":"2026-10-29","description":{"ar":"تم منح التوسيع التنظيمي في 29 أكتوبر 2026 لمرضى الأطفال المصابين بالأنيميا المنجلية وبيتا ثلاسيميا.","de":"Regulatorische Erweiterung am 29. Oktober 2026 für pädiatrische Patienten erteilt.","en":"Regulatory extension granted on 29 October 2026 for pediatric sickle-cell and beta-thalassaemia patients.","es":"Ampliación regulatoria concedida el 29 de octubre de 2026 para pacientes pediátricos falciformes y con talasemia.","fr":"Extension réglementaire accordée le 29 octobre 2026 pour les patients pédiatriques atteints de drépanocytose et thalassémie.","pt":"Extensão regulamentar concedida em 29 de outubro de 2026 para doentes pediátricos com drepanocitose e talassemia.","tr":"Pediatrik orak hücre ve beta talasemi hastaları için 29 Ekim 2026'da mevzuat genişletmesi yapıldı."},"label":{"ar":"وكالة MHRA توسع ترخيص كاسجيفي ليشمل الأطفال من سن 5 سنوات فما فوق","de":"MHRA erweitert Casgevy-Alterszulassung auf Kinder ab 5 Jahren","en":"MHRA expands Casgevy age authorisation to children aged 5 and over","es":"La MHRA amplía la autorización de Casgevy a niños a partir de 5 años","fr":"La MHRA élargit l'autorisation de Casgevy aux enfants de 5 ans et plus","pt":"MHRA alarga autorização do Casgevy a crianças a partir dos 5 anos","tr":"MHRA, Casgevy yaş yetkisini 5 yaş ve üzerine genişletti"},"status":"occurred"}],"methodology":{"ar":"يسجل التاريخ يوم نشر المصدر الأولي المشار إليه. ويحدد النطاق التنظيمي وفئات الأعمار في المادة.","de":"Das Datum bezeichnet die Veröffentlichung der angeführten Primärquelle. Regulatorischer Geltungsbereich und Altersgrenzen werden im Artikel dargelegt.","en":"The date records publication of the cited primary source. Regulatory scope and age indications are stated in the article.","es":"La fecha registra la publicación de la fuente primaria citada. El alcance regulatorio y las indicaciones de edad se detallan en el artículo.","fr":"La date correspond à la publication de la source primaire citée. Le périmètre réglementaire et les indications d'âge sont précisés dans l'article.","pt":"A data regista a publicação da fonte primária citada. O âmbito regulamentar e os escalões etários são detalhados no artigo.","tr":"Tarih, atıf yapılan birincil kaynağın yayımlandığı günü gösterir. Düzenleyici kapsam ve yaş endikasyonları haberde belirtilmiştir."},"sourceUrls":["https://www.gov.uk/government/news/mhra-approves-gene-editing-treatment-for-children-aged-five-and-over-with-serious-inherited-blood-disorders"],"title":{"ar":"نشر المصدر","de":"Quellenveröffentlichung","en":"Source publication","es":"Publicación de la fuente","fr":"Publication de la source","pt":"Publicação da fonte","tr":"Kaynak yayını"},"type":"events","updatedAt":"2026-11-01T00:43:00Z"}],"version":1},"data_downloads":[{"formats":{"csv":"https://newsverum.com/api/v1/articles/uk-mhra-casgevy-gene-editing-children-approval-2026/data/source-announcement?lang=en&format=csv","json":"https://newsverum.com/api/v1/articles/uk-mhra-casgevy-gene-editing-children-approval-2026/data/source-announcement?lang=en&format=json"},"id":"source-announcement"}],"data_types":["events"],"editorial_illustration":{"alt":"Conceptual illustration of public health, research and connected data.","asset_id":"newsverum-v1-health","avif_variants":[{"height":320,"url":"https://newsverum.com/assets/newsverum/illustrations/v1/health-480.avif","width":480},{"height":480,"url":"https://newsverum.com/assets/newsverum/illustrations/v1/health-720.avif","width":720},{"height":640,"url":"https://newsverum.com/assets/newsverum/illustrations/v1/health-960.avif","width":960},{"height":800,"url":"https://newsverum.com/assets/newsverum/illustrations/v1/health-1200.avif","width":1200},{"height":1024,"url":"https://newsverum.com/assets/newsverum/illustrations/v1/health-1536.avif","width":1536}],"caption":null,"credit":"Newsverum","documentary":false,"height":1024,"kind":"symbolic-editorial-illustration","language":"en","scope":"topic","url":"https://newsverum.com/assets/newsverum/illustrations/v1/health-1536.webp","variants":[{"height":320,"url":"https://newsverum.com/assets/newsverum/illustrations/v1/health-480.webp","width":480},{"height":640,"url":"https://newsverum.com/assets/newsverum/illustrations/v1/health-960.webp","width":960},{"height":1024,"url":"https://newsverum.com/assets/newsverum/illustrations/v1/health-1536.webp","width":1536}],"width":1536},"event_id":"event-3de095f4-3470-5d3b-a037-614eb4c44b2f","event_period":"2026-10-29","event_period_basis":"event-or-reference-period","id":"uk-mhra-casgevy-gene-editing-children-approval-2026","image":null,"importance":0.6,"language":"en","modified_at":"2026-11-01T00:43:00Z","publication_basis":"publication-record","published_at":"2026-10-31T22:01:30+00:00","reading_minutes":1,"region":"world","relations":[],"section_illustration":{"alt":"Conceptual illustration of public health, research and connected data.","asset_id":"newsverum-v1-health","avif_variants":[{"height":320,"url":"https://newsverum.com/assets/newsverum/illustrations/v1/health-480.avif","width":480},{"height":480,"url":"https://newsverum.com/assets/newsverum/illustrations/v1/health-720.avif","width":720},{"height":640,"url":"https://newsverum.com/assets/newsverum/illustrations/v1/health-960.avif","width":960},{"height":800,"url":"https://newsverum.com/assets/newsverum/illustrations/v1/health-1200.avif","width":1200},{"height":1024,"url":"https://newsverum.com/assets/newsverum/illustrations/v1/health-1536.avif","width":1536}],"caption":null,"credit":"Newsverum","documentary":false,"height":1024,"kind":"symbolic-editorial-illustration","language":"en","scope":"section","url":"https://newsverum.com/assets/newsverum/illustrations/v1/health-1536.webp","variants":[{"height":320,"url":"https://newsverum.com/assets/newsverum/illustrations/v1/health-480.webp","width":480},{"height":640,"url":"https://newsverum.com/assets/newsverum/illustrations/v1/health-960.webp","width":960},{"height":1024,"url":"https://newsverum.com/assets/newsverum/illustrations/v1/health-1536.webp","width":1536}],"width":1536},"slug":"uk-mhra-casgevy-gene-editing-children-approval-2026","sources":[{"checkedAt":"2026-11-01","name":"Medicines and Healthcare products Regulatory Agency, United Kingdom","publishedAt":"2026-10-29","url":"https://www.gov.uk/government/news/mhra-approves-gene-editing-treatment-for-children-aged-five-and-over-with-serious-inherited-blood-disorders"}],"summary":"The UK Medicines and Healthcare products Regulatory Agency announced on 29 October that it has expanded the authorisation for the CRISPR-based gene therapy Casgevy to children aged five and older with severe sickle-cell disease and transfusion-dependent beta-thalassaemia.","text":"The UK Medicines and Healthcare products Regulatory Agency announced on 29 October that it has expanded the authorisation for the CRISPR-based gene therapy Casgevy to children aged five and older with severe sickle-cell disease and transfusion-dependent beta-thalassaemia.\n\nThe UK Medicines and Healthcare products Regulatory Agency announced on 29 October that it has expanded the authorisation for the CRISPR-based gene therapy Casgevy to children aged five and older with severe sickle-cell disease and transfusion-dependent beta-thalassaemia.\n\nCasgevy (exagamglogene autotemcel) was previously restricted to patients aged 12 and above. The therapy edits the patient’s harvested haematopoietic stem cells in a laboratory to reactivate fetal haemoglobin production, before reinfusing them following myeloablative conditioning.\n\nThe regulator confirmed that the expansion follows evaluation of clinical trials demonstrating significant reductions in vaso-occlusive pain crises and transfusion dependency in younger age cohorts. Treatment requires specialized cell-therapy centres and rigorous post-infusion monitoring for complications such as cytopenias and infections.","title":"UK MHRA extends Casgevy gene-editing approval to children aged five and over","topics":[],"translations":[{"api_url":"https://newsverum.com/api/v1/articles/uk-mhra-casgevy-gene-editing-children-approval-2026?lang=tr","language":"tr","url":"https://newsverum.com/tr/news/uk-mhra-casgevy-gene-editing-children-approval-2026"},{"api_url":"https://newsverum.com/api/v1/articles/uk-mhra-casgevy-gene-editing-children-approval-2026?lang=en","language":"en","url":"https://newsverum.com/en/news/uk-mhra-casgevy-gene-editing-children-approval-2026"},{"api_url":"https://newsverum.com/api/v1/articles/uk-mhra-casgevy-gene-editing-children-approval-2026?lang=ar","language":"ar","url":"https://newsverum.com/ar/news/uk-mhra-casgevy-gene-editing-children-approval-2026"},{"api_url":"https://newsverum.com/api/v1/articles/uk-mhra-casgevy-gene-editing-children-approval-2026?lang=fr","language":"fr","url":"https://newsverum.com/fr/news/uk-mhra-casgevy-gene-editing-children-approval-2026"},{"api_url":"https://newsverum.com/api/v1/articles/uk-mhra-casgevy-gene-editing-children-approval-2026?lang=es","language":"es","url":"https://newsverum.com/es/news/uk-mhra-casgevy-gene-editing-children-approval-2026"},{"api_url":"https://newsverum.com/api/v1/articles/uk-mhra-casgevy-gene-editing-children-approval-2026?lang=de","language":"de","url":"https://newsverum.com/de/news/uk-mhra-casgevy-gene-editing-children-approval-2026"},{"api_url":"https://newsverum.com/api/v1/articles/uk-mhra-casgevy-gene-editing-children-approval-2026?lang=pt","language":"pt","url":"https://newsverum.com/pt/news/uk-mhra-casgevy-gene-editing-children-approval-2026"}],"url":"https://newsverum.com/en/news/uk-mhra-casgevy-gene-editing-children-approval-2026"},"version":"1"}
